(NASDAQ: CBUS) Cibus's forecast annual revenue growth rate of 145.41% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 32.02%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.47%.
Cibus's revenue in 2026 is $4,347,000.On average, 5 Wall Street analysts forecast CBUS's revenue for 2026 to be $636,729,699, with the lowest CBUS revenue forecast at $496,941,124, and the highest CBUS revenue forecast at $778,428,998. On average, 5 Wall Street analysts forecast CBUS's revenue for 2027 to be $1,180,598,207, with the lowest CBUS revenue forecast at $976,609,302, and the highest CBUS revenue forecast at $1,384,357,825.
In 2028, CBUS is forecast to generate $5,707,103,600 in revenue, with the lowest revenue forecast at $5,483,319,593 and the highest revenue forecast at $5,874,941,605.